Leif Gothefors

Publications

Author

Title

Year sorteringsordning

Fulltext

Carlsson, R. M.
Gustafsson, L.
Hallander, H. O.; et al.

Two consecutive randomized controlled pertussis booster trials in children initially vaccinated in infancy with an acellular vaccine: The first with a five-component Tdap vaccine to 5-year olds and the second with five- or monocomponent Tdap vaccines at age 14-15 years
Vaccine, 33(31): 3717-3725

2015

-

Rinder, Malin
Tran, Anh Nhi
Bennet, Rutger; et al.

Burden of severe rotavirus disease leading to hospitalization assessed in a prospective cohort study in Sweden
Scandinavian Journal of Infectious Diseases, 46(4): 294-302

2014

-

Prymula, Roman
Bergsaker, Marianne Riise
Esposito, Susanna; et al.

Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial
The Lancet, 383(9925): 1313-1324

2014

-

Gothefors, Leif
Trollfors, Birger

Vaccinationsprogrammet efter HPV? Vad övrigt är, är tystnad.
Läkartidningen, 109(8): 384-384

2012

-

Myléus, Anna
Hernell, Olle
Gothefors, Leif; et al.

Early infections are associated with increased risk for celiac disease: an incident case-referent study
BMC Pediatrics, 12(1): 194-

2012

Download

Myleus, Anna
Stenlund, Hans
Hernell, Olle; et al.

Early vaccinations are not risk factors for Celiac Disease
Pediatrics, 130(1): E63-E70

2012

-

Gothefors, Leif
Hernell, Olle

Diarré och magsjuka – prevention och behandling
Små & stora nyheter

2011

-

Carlsson, Rose-Marie
Blennow, Margareta
Gothefors, Leif

Vaccination av barn och ungdomar (ingår i Läkemedelsboken 2011-2012)

2011

-

Van der Wielen, Marie
Giaquinto, Carlo
Gothefors, Leif; et al.

Impact of community-acquired paediatric rotavirus gastroenteritis on family life: data from the REVEAL study.
BMC Family Practice, 11: 22-

2010

-

Itzler, Robbin
Koch, Gary
Matson, David O; et al.

Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5).
BMC Pediatrics, 10(1): 42-

2010

-